Gilder Gagnon Howe & Co. LLC Increases Position in Glaukos Co. (NYSE:GKOS)

Gilder Gagnon Howe & Co. LLC raised its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 25.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 825,276 shares of the medical instruments supplier's stock after acquiring an additional 166,677 shares during the period. Glaukos makes up about 1.3% of Gilder Gagnon Howe & Co. LLC's investment portfolio, making the stock its 19th largest position. Gilder Gagnon Howe & Co. LLC owned 1.50% of Glaukos worth $123,742,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GKOS. Coldstream Capital Management Inc. bought a new position in Glaukos in the fourth quarter worth approximately $208,000. Science & Technology Partners L.P. bought a new position in shares of Glaukos during the fourth quarter valued at approximately $7,759,000. Voya Investment Management LLC increased its holdings in Glaukos by 266.2% during the fourth quarter. Voya Investment Management LLC now owns 200,698 shares of the medical instruments supplier's stock valued at $30,093,000 after buying an additional 145,890 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Glaukos by 13.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 35,182 shares of the medical instruments supplier's stock worth $5,276,000 after buying an additional 4,227 shares during the period. Finally, Stifel Financial Corp boosted its position in Glaukos by 2.6% during the 4th quarter. Stifel Financial Corp now owns 4,341 shares of the medical instruments supplier's stock valued at $651,000 after acquiring an additional 111 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Performance

NYSE:GKOS traded down $14.54 during trading hours on Thursday, reaching $79.71. The company had a trading volume of 2,198,824 shares, compared to its average volume of 658,597. The firm has a market cap of $4.55 billion, a PE ratio of -27.77 and a beta of 0.88. Glaukos Co. has a 1-year low of $77.56 and a 1-year high of $163.71. The business's 50 day moving average price is $99.10 and its 200-day moving average price is $129.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. During the same quarter in the previous year, the company earned ($0.70) earnings per share. The firm's revenue for the quarter was up 24.6% on a year-over-year basis. Research analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Insider Buying and Selling at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GKOS has been the topic of a number of recent research reports. Truist Financial reaffirmed a "buy" rating and set a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a research report on Thursday. Mizuho reduced their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Stifel Nicolaus lowered their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $160.00 to $86.00 in a report on Thursday. Finally, Needham & Company LLC decreased their price target on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $139.50.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.